Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
暂无分享,去创建一个
U. Banerji | S. Kaye | T. Yap | M. O'Brien | J. D. de Bono | S. Popat | K. Rihawi | D. Roda | M. Capelán | J. Bhosle | S. Bodla | E. Geuna
[1] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[2] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[3] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[4] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[5] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[6] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[7] J. Neal,et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.
[8] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[9] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[12] P. Jänne,et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Fairclough,et al. Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1) , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] F Levi,et al. European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] R. Plummer,et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[17] S. Teerenstra,et al. Reply letter to: pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant - reply to Füssenich et al.: a new, simple and objective prognostic score for phase I cancer patients. , 2012, European journal of cancer.
[18] B. Kholodenko,et al. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. , 2012, Biochemical Society transactions.
[19] P. Workman,et al. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. , 2012, Annual review of pharmacology and toxicology.
[20] S. Digumarthy,et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[22] J. Blenis,et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.
[23] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[24] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[25] Paul Workman,et al. Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.
[26] Paul D. Smith,et al. The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer , 2010, Clinical Cancer Research.
[27] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Lucio Crinò,et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.
[30] S. Kaye,et al. Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. , 2012, European journal of cancer.